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Over the past 5 yr several inactivating mutations in the
LH receptor gene have been demonstrated to cause Leydig
cell hypoplasia, a rare autosomal recessive form of male
pseudohermaphroditism. Here, we report the identification of
two new LH receptor mutations in a compound heterozygous
case of complete Leydig hypoplasia and determine the cause
of the signaling deficiency at a molecular level. On the pater-
nal allele of the patient we identified in codon 343 a T to A
transversion that changes a conserved cysteine in the hinge
region of the receptor to serine (C343S); on the maternal allele
a T to C transition causes another conserved cysteine at codon
543 in trans-membrane segment 5 to be altered to arginine
(C543R). Both of these mutant receptors are completely de-
void of hormone-induced cAMP reporter gene activation. Us-
ing Western blotting of expressed LH receptor protein with a
hemagglutinin tag, we further show that despite complete
absence of total and cell surface hormone binding, protein
levels of both mutant LH receptors are only moderately af-
fected. The expression and study of enhanced green fluores-
cent protein-tagged receptors confirmed this view and fur-
ther indicated that initial translocation to the endoplasmic
reticulum of these mutant receptors is normal. After that,
however, translocation is halted or misrouted, and as a result,
neither mutant ever reaches the cell surface, and they cannot
bind hormone. This lack of processing is also indicated by
reduced presence of an 80-kDa protein, the only N-linked gly-
cosylated protein in the LH receptor protein profile. Thus,
complete lack of signaling by the identified mutant LH recep-
tors is caused by insufficient processing from the endoplasmic
reticulum to the cell surface and results in complete Leydig
cell hypoplasia in this patient. (J Clin Endocrinol Metab 87:
2506–2513, 2002)
AMONG THE VARIOUS disorders of sex differentiation,male pseudohermaphroditism is defined as a defec-
tive masculinization of internal and/or external genitalia in
46,XY individuals. Male pseudohermaphroditism can be
caused by gonadal dysgenesis or defects in T action, such as
androgen insensitivity or 5-reductase deficiency (1). An-
other cause of male pseudohermaphroditism is defective T
synthesis as a consequence of an enzymatic defect in the
steroidogenic pathway or an anomaly in Leydig cell differ-
entiation referred to as Leydig cell hypoplasia (LCH).
LCH is a rare form of male pseudohermaphroditism
with an autosomal recessive pattern of inheritance (2– 6).
LCH patients present with a female phenotype, primary
amenorrhea, absence of secondary sex differentiation at
puberty, and elevated LH levels with abnormally low T
levels. In the testes of these patients mature Leydig cells
are absent, indicating a primary defect of Leydig cell de-
velopment. In addition, milder forms of LCH have been
described in phenotypic males with micropenis and/or
hypospadias (7–10).
The underlying gene defect in LCH was first identified
by Kremer et al. (11). They observed a homozygous mis-
sense mutation in the LH receptor (LHR) gene in a patient
with the severe form of LCH. The mutation resulted in an
alanine to proline transition in the sixth trans-membrane
segment of the LHR protein, which completely obliterated
transduction of the signal of LH binding to an intracellular
increase in cAMP. After this report, a number of different
LHR gene mutations were identified in patients with LCH,
including in males with hypospadias and micropenis (re-
viewed in Refs. 12–16). As may be expected, the inacti-
vating LHR gene mutations are not only found in the
trans-membrane domain, but are scattered throughout the
protein. In addition, the mutations include not only mis-
sense mutations, but also nonsense mutations and small
and large deletions and insertions, all leading to a com-
pletely or partially inactive receptor molecule.
In the present paper we report the identification of two
novel LHR mutations that cause LCH in the described pa-
tient. In addition, using enhanced green fluorescent protein
Abbreviations: EGFP, Enhanced green fluorescent protein; ER, en-
doplasmic reticulum; HA, hemagglutinin; hLHR, human LH receptor;
LCH, Leydig cell hypoplasia.
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(EGFP)-tagged receptors we show that lack of signaling by
the mutant receptors is caused by aberrant intracellular pro-
cessing of the mutant LHR protein.
Subjects and Methods
Subject
The patient was born at term after uncomplicated pregnancy and
delivery as the first child of unrelated parents of Caucasian origin. No
family history was noted. She presented at the age of 12 yr with a female
phenotype and inguinal hernias. Further examination revealed a 46,XY
karyotype, cryptorchid testes in the inguinal canal, a blind vaginal
pouch, and absence of Mu¨llerian duct derivatives. At the age of 14 yr no
breast development was observed. T levels were low (0.21 ng/ml) and
did not respond to an hCG stimulation test (0.19 ng/ml). In contrast, LH
levels were high (68 IU/liter) and increased to 150 IU/liter after a GnRH
challenge. Histological analysis of the testes, which were removed at 14
yr of age, revealed seminiferous tubules surrounded by thick hyalinized
walls and absent spermatogenesis. In the interstitial space few imma-
ture, but no mature, Leydig cells could be found. Informed consent for
this study was obtained from the mother of the subject.
Mutational analysis
Genomic DNA was extracted from peripheral blood obtained from
the patient and her mother. Using PCR, two overlapping fragments of
exon 11 of the LHR gene were amplified with two primer sets: primer
set 1: LHR1, 5-ggctgaggctattatggcttt-3 (in intron 10); and LHR2, 5-
tggggaagcaaatactgacc-3; and primer set 2: LHR3, 5-aagatggcacaccat-
cacct-3; and LHR4, 5-tttcctaaatccaaccctttatg-3. The PCR products (720
and 810 bp, respectively) were verified using gel electrophoresis, pu-
rified, and subsequently manually sequenced using a commercial se-
quencing kit (Amersham Pharmacia Biotech, Saclay, France). The se-
quence samples were analyzed on standard denaturing acrylamide gels
(17).
Construction of the mutant LHR cDNA expression vectors
The coding region of the LHR, extended with an immunotag [hem-
agglutinin 1 (HA1)] at the C-terminus (18), was placed downstream of
the simian virus 40 large T antigen promoter in the expression plasmid
pSG5 (19, 20), resulting in pSG5-human (h) LHR. The HA1 tag does not
affect expression and signal transduction of the wild-type LHR (18).
pSG5-hLHR-EGFP was constructed by inserting in-frame the EGFP cod-
ing sequence immediately downstream of the last codon of the LHR
open reading frame. Therefore, EGFP was excised from pEGFP-N1
(CLONTECH Laboratories, Inc., Palo Alto, CA) as an SmaI-HpaI (nu-
cleotides 658 to 1518) fragment and cloned in the unique HpaI site of
pSG5-hLHR. The C543R mutation was introduced in the expression
vectors pSG5-hLHR and pSG5-hLHR-EGFP using a previously de-
scribed approach (20), except that primers LHR543CRFOR (5-gccttct-
tcataattcgtgcttgctacatt-3) and LHR543CRREV (5-aatgtagcaagcacgaat-
tatgaagaaggc-3) were used in the first PCR amplification reaction. The
mutant expression vector obtained was named pSG5-hLHRC543R. For
the C343S substitution, a 1028-bp fragment was obtained in a two-step
PCR amplification strategy using the flanking primers 181FOR (5-
ctccctgtcaaagtgatcc-3) and 11.1REV (5-attgcacatgagaaaacgagg-3).
The mutation was introduced in the first PCR step using
primers LHR343CSFOR (5-ttacccaagacaccccgaagtgctcctgaa-3) and
LHR343CSREV (5-ttcaggagcacttcggggtgtcttgggtaa-3). The amplified
mutated DNA fragment was digested with HindIII and Bsu36 I (posi-
tions 202 and 1082 of the LHR open reading frame), and the resulting
fragment was exchanged for the wild-type HindIII-Bsu36 I fragment in
pSG5-hLHR and pSG5-hLHR-EGFP, resulting in pSG5-hLHRC343S and
its EGFP extended analog. Primers were purchased from Eurogentec
(Seraing, Belgium), and mutagenesis was verified by DNA sequence
analysis of the exchanged fragments.
Analysis of signal transduction and hCG binding
COS-1 cells were maintained as previously described (18). For esti-
mation of hormone-dependent induction of cAMP and total and cell
surface binding, subconfluent COS-1 cells were transiently transfected
(21) with 2 g of the cAMP-reporter plasmid pCRE6Lux (22); 1 g
pRSVlacZ (23) as a control for transfection efficiency; 10 g pSG5, pSG5-
hLHR, pSG5-hLHR-EGFP, pSG5-hLHRC343S, or pSG-hLHRC543R; and
8 g carrier DNA/75 cm2 culture flask. In the receptor cotransfection
experiment, 5 g of each receptor expression plasmid were combined.
Two days after transfection the cells were trypsinized and plated in
24-well tissue culture plates (Nunc, Roskilde, Denmark) for luciferase
and -galactosidase measurements and in a 75-cm2 tissue culture flask
(Nunc) for total and cell surface hCG binding. To determine the cAMP
response, cells were incubated the next day in culture medium contain-
ing 0.1% BSA and the indicated concentration of hCG (Organon, Oss,
The Netherlands). After 6 h the cells were lysed, and luciferase activity
was determined (24). hCG binding to intact cells as well as to cell
membranes was performed as described previously (18, 25).
Western blotting
SDS-PAGE was performed essentially as described previously (18).
Briefly, COS-1 cells were transfected with 10 g of the expression vector
pSG5 containing the indicated HA1-tagged LHR cDNA. Three days after
transfection, the cells were harvested, and equal amounts of protein (10
g) were separated using 10% SDS-PAGE. To remove N-linked glyco-
sylated groups, samples were boiled and treated with N-glycosidase F
(Roche Molecular Biochemicals). After Western transfer, LHR protein
was visualized using an HA1-specific monoclonal antibody in combi-
nation with the Renaissance chemiluminescence detection kit (NEN Life
Science Products, Du Pont de Nemours, Dreieich, Germany).
Microscopic analysis of hLHR-EGFP in COS-1 cells
COS-1 cells were transfected by the calcium phosphate DNA pre-
cipitation method (see above) on 2  2 cm2 Lab-Tek chamber slides
(Nunc, Naperville, IL) with 2 g pSG5-hLHR-EGFP, pSG5-hLHRC343S-
EGFP, or pSG5-hLHRC543R-EGFP. Twelve hours after transfection, pre-
cipitate was removed and replaced by fresh medium with 0.1% (wt/vol)
BSA. The living cells were observed directly on the chamber slide using
an inverted fluorescence microscope (Diaphot 200, Nikon, Champigny-
sur-Marne, France) with a fluorescein isothiocyanate filter. This micro-
scope was coupled to a CCD camera (Night Owl, EGG-Berthold, Evry,
France) to record cells. The cells were first observed after 24, 48, and 72 h
of transfection.
Results
Sequence analysis of exon 11 of the LHR gene
Sequence analysis of two overlapping PCR fragments of
exon 11 of the LHR gene derived from genomic DNA re-
vealed two heterozygous missense mutations (Fig. 1). At
codon 343 we identified a TGT to AGT change resulting in
a change from cysteine to serine at the protein level (Fig. 1A).
In addition, a TGT to CGT modification was found at codon
543 that changed the cysteine at this position to arginine (Fig.
1B). The mother of the proband was also heterozygous at
codon 543 for same mutation, indicating that this mutant
allele was maternal. Unfortunately, DNA from the father was
not available. The patient did not inherit both mutations from
the mother, as we observed a homozygous wild-type se-
quence at codon 343 in the maternal DNA sample (Fig. 1A).
Thus, the missense mutation at codon 343 was either derived
from the father or had occurred de novo.
Biochemical characterization and functional analysis of
mutant receptors
To determine the effects of the missense mutations on the
LHR protein, wild-type LHR and the two mutant receptors
were expressed in COS-1 cells and visualized using Western
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blotting (Fig. 2). In the control lane, containing proteins from
COS-1 cells transfected with the empty expression vector
pSG5, one protein band with molecular mass of 90 kDa was
observed (Fig. 2, asterisks). As previously described, this band
was due to nonspecific interaction of the HA1 antibody with
an endogenous protein of COS-1 cells (18). In addition to this
nonspecific signal, several bands of different intensities and
molecular masses were observed in the COS-1 cells trans-
fected with wild-type LHR. These bands probably represent
different forms (glycosylated and/or multimerized) of the
LHR protein. In addition to the two clearly visible bands with
molecular masses of 75 and 80 kDa (indicated with arrows),
multiple protein bands of different intensities of 150 kDa and
larger were present. These latter bands may be the result of
nonspecific association or incomplete solubilization of the
hydrophobic LHR proteins. The appearance of the 80-kDa
protein band was not sharp, suggesting that it may consist
of multiple similarly sized proteins. In COS-1 cells trans-
fected with the mutant LHR expression constructs, pSG5-
hLHRC343S and pSG5-hLHRC543R, a similar pattern of pro-
tein bands was observed, with the distinct exception of the
80-kDa protein (Fig. 2), which is much more abundant in the
wild-type LHR-expressing cells. In addition, the intensity of
all LHR-specific bands, especially the 75-kDa band, was re-
duced in COS-1 cells transfected with pSG5-hLHRC543R,
suggesting that the expression of total LHR protein of this
mutant receptor was slightly reduced. N-Glycosidase F treat-
ment of the samples resulted in the complete disappearance
of the heterogeneous 80-kDa band from both wild-type and
mutant LHR-transfected cell extracts, indicating that this
particular protein is N-glycosylated. None of the other bands
showed a clear reduction in size after treatment, indicating
that N-linked glycosyl groups are small, completely absent,
or not accessible to the enzyme. The heterogeneous feature
of the 80-kDa protein agrees with the fact that it is an N-
linked glycosylated protein, because N-linked glycosylation
is often heterogeneous (26).
Subsequently, we determined whether the mutant recep-
tors after synthesis were properly transported to the cell
surface and were able to display proper ligand binding. Cells
transfected with pSG5-hLHR showed high affinity binding
(Kd  3.5 nm) and a number of receptors equivalent to pre-
vious experiments (binding capacity, 25 fmol/mg protein)
(18), whereas no binding was detectable to intact cells
transfected with either the pSG5-hLHRC343S or pSG5-
hLHRC543R expression vector (Table 1). These results indi-
FIG. 1. Two heterozygous missense mutations were identified in LCH patient. Genomic sequence in the region of codon 343 (A) and codon 543
(B) of the LHR gene of the patient and her mother are shown. Mutations are indicated with an asterisk. The patient, but not her mother, is
heterozygous at codon 343 for a T to A base change that results in an amino acid change from Cys to Ser; the patient and her mother are both
heterozygous at codon 543 for a T to C nucleotide change that results in an amino acid change from Cys to Arg.
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cate that the number of mutant receptor molecules present on
the cell surface was too low to be detected. Subsequently, we
determined the total hCG binding capacity of wild-type and
mutant LHR-transfected COS-1 cells (Table 2). The binding
capacity of solubilized extracts derived from COS-1 cells
transfected with either mutant receptor was not different
from that of cells transfected with the empty expression
vector. However, solubilized extracts from cells transfected
with the wild-type LHR showed considerable binding
capacity.
We determined whether the mutant receptors have a re-
sidual ability to transduce the hormonal signal despite
undetectable cell surface binding and absent cell surface
localization. Cells transfected with pSG5-hLHR showed a
vigorous response to increasing concentrations of hCG, with
an ED50 of approximately 5 ng/ml (Fig. 3A). In contrast, cells
expressing hLHRC343S or hLHRC543R did not respond to
hCG, indicating that the mutant receptors are completely
deficient in signaling (Fig. 3A). To mimic the heterozygous
phenotype of this patient in vitro, we also transfected both
TABLE 2. [125I]hCG binding to solubilized COS-1 cells expressing
wild-type and mutant LH receptors
Wild-type hLHR hLHRC343S hLHRC543R
Specific bindinga 1177  22 28  12b 99  43b
a Specific binding is expressed as counts per min/g total protein.
b Binding not detectably different from empty vector-transfected
COS-1 cells. Specific binding to membranes of empty vector-trans-
fected COS-1 cells was 31  16 cpm/g total protein.
FIG. 2. Expression of the mutant LHR cDNAs in COS-1 cells. COS-1
cells were transfected with the indicated HA-tagged expression vec-
tors. Three days after incubation, the cells were lysed, and equal
amounts of total protein were loaded in Laemmli sample buffer on a
10% SDS-PAGE gel. The indicated samples were treated with N-
glycosidase F. After Western blotting, specific protein bands were
visualized using a monoclonal antibody against the HA tag present at
the C-terminus of the LHR protein. The asterisks indicate a nonspe-
cific band present in COS-1 cells. The arrows indicate the two lower
molecular mass LHR proteins of 75 and 80 kDa. The abundance of the
N-linked glycosylated 80-kDa protein is clearly reduced in both mu-
tant receptors.
TABLE 1. Scatchard analysis of [125I]hCG binding to intact COS-
1 cells expressing wild-type and mutant LH receptors
Wild-type hLHR hLHRC343S hLHRC543R
Kd (nM) 3.5 — —
Bmax 25 —
a —a
Bmax is expressed as femtomoles per mg total protein.
a Number of binding sites not detectably different from empty
vector-transfected COS-1 cells. Specific binding to intact empty vector
transfected COS-1 cells was undetectable to low.
FIG. 3. hCG induction of cAMP response element reporter activity by
different LHR cDNAs expressed in COS-1 cells. COS-1 cells, cotrans-
fected with the indicated LHR expression vector, a cAMP-responsive
luciferase reporter plasmid, and a -galactosidase reporter plasmid
driven by a constitutively promoter, were incubated in the presence
of the indicated concentrations of hCG. Luciferase activity measured
in the cell lysates and normalized for -galactosidase activity is pre-
sented. The results of one experiment of two performed are shown and
are presented as the mean  SD (n  4). A, hLHRC343S and
hLHRC543R, but not the wild-type receptor, are completely devoid of
hCG-dependent signal transduction. B, Wild-type hLHR and its
EGFP-extended analog display identical hormone-dependent CRE
activation.
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mutant receptors simultaneously (not shown). Cells trans-
fected with a single defective LHR as well as cells transfected
with the two mutant LHR cDNAs together showed no de-
tectable hCG-induced reporter activity. Thus, these two mu-
tant receptors cannot complement each other in vitro, in line
with the complete LCH phenotype observed in this patient.
The absence of complementation contrasts with previous
findings that severely N- and C-terminal truncated LHRs
were able to complement each other (27). The difference may
be that point mutations that block signaling are not suffi-
ciently disruptive to induce the formation of receptor
hybrids.
The complete absence of ligand binding and, therefore,
signaling of both mutant LHRs contrasted with their near-
normal protein expression levels, as demonstrated by West-
ern blotting. To localize the mutant receptor protein in the
cell we constructed LHR isoforms that were extended at the
C-terminal end with an EGFP fusion protein that can be
visualized using fluorescence microscopy. In COS-1 cells the
wild-type LHR fused to EGFP displayed similar cell surface
binding as the wild-type LHR without EGFP (not shown).
Moreover, hormone (hCG)-dependent signal transduction,
as measured by cAMP-responsive element activation, was
also indistinguishable from that of wild-type LHR (Fig. 3B),
indicating that extension of the LHR molecule with an EGFP
fusion at the C-terminus has no detectable effect on receptor
function. Subsequently, localization of mutant and wild-type
LHR was studied at different time points after transfection
in COS-1 cells (Fig. 4). Interestingly, 24 h after transfection
both the two mutant and the wild-type receptors showed
similar localization. At this time, localization resembled en-
doplasmic reticulum (ER) staining consisting mainly of in-
tense vesicular perinuclear and nuclear membrane fluores-
cence (28–29a). At 48 h the pattern for the wild-type receptor,
however, had significantly changed. At that time cell surface
fluorescence appeared (Fig. 4, arrow) while the intense pe-
rinuclear staining remained visible. At 72 h the picture was
similar, except that cell surface staining was more pro-
nounced. The pattern for both mutant receptors was clearly
different from that of the wild-type LHR. At 48 h the vesic-
ular phenotype was still visible, but seemed less closely
localized to the perinuclear area, with more widespread dis-
tribution throughout the cytoplasm. In addition, some small
and large foci appeared, suggesting that the mutant receptor
molecules may have trafficked in part beyond the ER com-
partment. At 72 h, these foci were more visible, particularly
the large ones. These large vesicles were not observed in
wild-type receptor-transfected cells. Cell surface fluores-
cence of EGFP was never observed with either mutant LHR.
Discussion
The present report describes two compound heterozygous
missense mutations in the LHR gene that cause a complete
form of Leydig cell hypoplasia and determines the molecular
mechanism that underlies the signaling deficiency.
Two new inactivating mutations in Leydig cell hypoplasia
The C543R amino acid change is located in the fifth trans-
membrane segment of the LHR molecule. Interestingly, at a
neighboring amino acid, I542, an activating mutation (I542L)
has been described (30, 31). Thus, amino acid changes at
FIG. 4. Subcellular localization of
EGFP-fused wild-type and mutant hL-
HRs in COS-1 cells. Cells were trans-
fected with the indicated LHR expres-
sion vectors and observed using an
inverted fluorescence microscope at 24,
48, and 72 h after transfection. At 24 h,
wild-type and mutants receptors pre-
sented similar perinuclear distribu-
tions. Cell surface localization of wild-
type receptor appeared at 48 h and
increased at 72 h (indicated with an ar-
row). In contrast, no mutant processed
to the cell surface. For both mutant re-
ceptors fluorescence remained cytoplas-
mic, with a widespread and heteroge-
neous distribution, including the
appearance of small and large foci.
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neighboring positions can lead to complete opposite receptor
activities. The opposite effects of the neighboring amino acid
changes may be due to the fact that cysteine 543, in contrast
to isoleucine 542, is directed toward the hydrophobic mem-
brane environment (18, 32, 33). The introduction of a charged
amino acid at position 543 may, therefore, disrupt proper
insertion of the transmembrane segment into the membrane,
similar to the suggested effect of a mutation in seventh trans-
membrane segment (I625K) previously found in another pa-
tient with LCH (18). A minor amino acid change, such as the
I542L mutation, may result in a less tight tertiary structure
that allows isomerization between the inactive and active
states, resulting in constitutive activity. As a result of this
loose tertiary structure, constitutively active G protein-
coupled receptors appear to be more vulnerable to inactiva-
tion (34), in part exemplified by diminished maximal activity
due to decreased cell surface hormone-binding activity (30,
35) (our unpublished results).
The other mutation, C343S, is located in the hinge region
of the LHR. This region is the least conserved domain among
glycoprotein hormone receptors, and its function, beyond
serving as a string of amino acids that connects the trans-
membrane domain of the receptor to the hormone-binding
domain, is not clear. Actually, in the marmoset monkey, exon
10, which encodes a large part of the hinge region, is not
present in the LHR molecule without affecting receptor func-
tion (36). Recently, an exon 10 deletion was identified in a
normally virilized boy with delayed puberty, indicating that
exon 10 may in part be involved in the specificity of recog-
nition of LH or hCG (37). Cysteine 343, however, is encoded
by exon 11 and is located in a small part of the hinge region
that is highly conserved (Fig. 5) in all glycoprotein hormone
receptors sequenced to date (GPCR database at the Univer-
sity of Nijmegen, Nijmegen, The Netherlands; http://www.
gpcr.org/7tm/). The importance of this conserved part of the
hinge region is underscored by the identification of an in-
activating alteration (E354K) in the same part of the hinge
region in another severe LCH patient (38).
Improper processing beyond the endoplasmic reticulum
Numerous mutant LHR molecules are signaling deficient
and devoid of ligand binding. Here we show that the ligand
binding-deficient mutant receptors C343S and C543R are
expressed at levels approaching that of the wild-type recep-
tor. By creating a fully functional EGFP-extended LHR we
have generated a new tool to study the expression and lo-
calization of LHR protein independent of ligand binding.
Our results show that mutant receptors initially arrive in the
same compartment as the wild-type receptor, which appears
to be the ER, although additional studies using ER marker
proteins are necessary to confirm this. The wild-type receptor
proceeds toward a state where it gains affinity for the ligand
and can reach the cell surface. The mutant receptors, how-
ever, are retained intracellularly, which coincides with the
reduced presence of the N-linked glycosylated 80-kDa pro-
tein, suggesting a lack of further processing. Other LHR
isoforms, the 75-kDa and the high molecular mass forms, are
not altered. Mutant LHRs A593P and S616Y, identified in
LCH patients, also showed concomitant reduction of the
80-kDa band and loss of cell surface hormone binding (18).
The mutant C343S and C543R LHRs, however, appear to
progress after translocation beyond the ER, finally ending up
in larger vesicular-like structures. Improper folding and/or
the absence of glycosyl groups may cause their different
fates. The mutant receptors either accumulate in a compart-
ment through which the wild-type LHR rapidly proceeds or
end up in a different compartment, possibly leading to deg-
radation of the protein. The presence of N-linked glycosyl
groups in one of mutant molecules suggests that at least
initially the same track is followed. The exact fate of the
mutant molecules is currently unknown and is subject to
further study.
The high molecular mass forms observed in the protein
profile may represent dimeric and multimeric forms of the
hLHR that play a direct role in signal transduction (39, 40),
or they may represent a precursor of the mature protein, as
has been shown for the rat LHR (41). Alternatively, the high
molecular mass forms may also be SDS-PAGE artifacts, com-
monly observed for G protein-coupled receptors and other
membrane-spanning proteins. Of the two lower molecular
mass forms only the 80-kDa form appeared to be N-linked
glycosylated. The 75-kDa protein clearly lacks N-linked gly-
cosyl groups and does not show hormone binding or cell
surface expression, as it is present in the mutant receptor
protein profile. Often the addition of glycosyl groups to
glycoproteins in the ER is required for most proteins to
acquire the active conformation (26, 42), although the role of
glycosylation in hormone binding to gonadotropin receptors
FIG. 5. Cysteine 343 is present in a small subdomain of the hinge region that is highly conserved. Amino acid sequence alignment of the hinge
region of the three human glycoprotein hormone receptors and of the recently identified human leucine-rich, repeat-containing, G protein-
coupled receptor LGR5. Boxed, uppercase, and lowercase amino acids underneath the alignment are identical in four, three, and two proteins,
respectively. Shaded amino acids are conserved in all glycoprotein hormone receptors. The amino acid number of the first amino acid of each
sequence is indicated. The cysteine mutated in this patient (indicated with the asterisk) is among the best conserved amino acids in the hinge
region of this receptor family present in the GPCR database (http://www.gpcr.org/7tm/). The alignment is taken from the report by Hsu et al.
(46). The glutamate and aspartate () were mutated in the studies by Huang et al. (47). The high conservation of this small part of the hinge
region suggests that this domain plays an important role in LHR signal transduction.
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remains controversial. Tunicamycin treatment showed that
the rat LHR does not require any N-linked glycosyl groups
for hormone binding (43), whereas the rat FSH receptor does
(44). However, direct mutagenesis in the rat LHR showed
that one particular N-linked glycosylation site that is con-
served in the human receptor is required for hormone bind-
ing (45). In the present study we show that the absence of the
glycosylated 80-kDa form of the LHR correlates with the lack
of hormone binding.
In conclusion, we have identified two novel LHR muta-
tions that collectively cause LCH in this patient. In addition,
we have determined that both mutants, despite almost nor-
mal protein expression, completely lack the capacity to bind
ligand and the ability to transduce the signal. In addition, the
N-linked glycosylated form of the receptor was almost absent
in protein profiles of both mutant receptors. Finally, using
novel GFP fusion proteins, we showed a defective translo-
cation of mutant LHR from the ER to the cell surface. Taken
together our data demonstrate that improper maturation of
LHR mutants is the primary cause of the complete signaling
defect leading to the absence of Leydig cell differentiation in
the patient.
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